Advisory-Sheldon_Kong.jpg

Executive Director, Health Economics and Outcomes Research Novo Nordisk, Inc.

Sheldon Kong, Ph.D. is currently Executive Director and Department Head, Health Economics and Outcomes Research at Novo Nordisk Inc. in Plainsboro, NJ. His team supports company strategy; develops and manages strategic research collaboration partnerships with payers, organized providers and academic centers; and generates, interprets and communicates health economic and real world evidence in the United States.

Prior to joining Novo Nordisk, he was the Department Head of Global Health Outcomes at Merck leading a team of health economists, epidemiologists, health service researchers, physicians, pharmacists and statisticians to develop strategy and evidence to support the global value proposition of its pharmaceuticals and vaccines. He was Assistant Professor of Pharmacy Administration at the University of Illinois at Chicago where he taught graduate level Pharmacoeconomics and Advanced Research Methods before joining the pharmaceutical industry and today still holds the appointment of Adjunct Professor of Pharmacy Systems, Outcomes and Policy. He also holds the appointment of Adjunct Professor and Corporate HEOR Advisory Board member at the Rutgers University Ernest Mario School of Pharmacy. He currently serves as a member of the HEOR Corporate Advisory Board of College of Pharmacy, University of Washington in Seattle.

Rating
Featured/Unfeatured
Claimed/Unclaimed

No entries were found.

Showing 0 results